<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZIOPTAN- tafluprost solution </strong><br>Merck Sharp &amp; Dohme Corp.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ZIOPTAN (tafluprost ophthalmic solution) 0.0015% safely and effectively. See full prescribing information for ZIOPTAN.<br><br> ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015%<br> Initial U.S. Approval: 2012</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc"><li>ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>. (<a href="#S1">1</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc"><li>One drop in the affected eye(s) once daily in the evening. (<a href="#S2">2</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Ophthalmic solution containing tafluprost 0.015 mg/mL. (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>None. (<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span></li></ul>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span> of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> is likely to be permanent. (<a href="#S5.1">5.1</a>) </p>
<ul class="Disc"><li>Eyelash Changes</li></ul>
<p class="Highlighta">Gradual changes to eyelashes including increased length, thickness and number of lashes. Usually reversible. (<a href="#S5.2">5.2</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>Most common ocular adverse reaction is <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span> (range 4% – 20%). (<a href="#S6.1">6.1</a>)</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Use in pediatric patients is not recommended because of potential safety concerns related to increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> following long-term chronic use. (<a href="#S8.4">8.4</a>)</li></ul></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Eyelash Changes</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5	Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14	CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1	Nightly Application</a></h2>
<h2><a href="#section-13.2" class="toc">17.2	Handling the Single-Use Container</a></h2>
<h2><a href="#section-13.3" class="toc">17.3	Potential for <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span></a></h2>
<h2><a href="#section-13.4" class="toc">17.4	Potential for Eyelash Changes</a></h2>
<h2><a href="#section-13.5" class="toc">17.5	When to Seek Physician Advice</a></h2>
<h2><a href="#section-13.6" class="toc">17.6	Use with Other Ophthalmic Drugs</a></h2>
<h2><a href="#section-13.7" class="toc">17.7	Storage Information</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one drop of ZIOPTAN in the conjunctival sac of the affected eye(s) once daily in the evening.</p>
<p>The dose should not exceed once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect.</p>
<p>Reduction of the intraocular pressure starts approximately 2 to 4 hours after the first administration with the maximum effect reached after 12 hours.</p>
<p>ZIOPTAN may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is being used, each one should be administered at least 5 minutes apart.</p>
<p>The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Ophthalmic solution containing tafluprost 0.015 mg/mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span></h2>
<p class="First">Tafluprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris, periorbital tissue (eyelid) and eyelashes. <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span> is expected to increase as long as tafluprost is administered. The <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of tafluprost, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris is likely to be permanent, while <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>. The long term effects of increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> are not known.</p>
<p>Iris color change may not be noticeable for several months to years. Typically, the brown <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with ZIOPTAN can be continued in patients who develop noticeably increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, these patients should be examined regularly. <span class="Italics">[See<a href="#S17.3"> Patient Counseling Information (17.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Eyelash Changes</h2>
<p class="First">ZIOPTAN may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, color, thickness, shape and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></h2>
<p class="First">ZIOPTAN should be used with caution in patients with active intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (e.g., <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>/<span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>) because the <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may be exacerbated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span>, including <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>, has been reported during treatment with prostaglandin F2α analogs. ZIOPTAN should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Studies Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>Preservative-containing or preservative-free tafluprost 0.0015% was evaluated in 905 patients in five controlled clinical studies of up to 24-months duration. The most common adverse reaction observed in patients treated with tafluprost was <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span> which was reported in a range of 4% – 20% of patients. Approximately 1% of patients discontinued therapy due to ocular adverse reactions.</p>
<p>Ocular adverse reactions reported at an incidence of ≥2% in these clinical studies included <span class="product-label-link" type="condition" conceptid="4201702" conceptname="Sore eye">ocular stinging</span>/irritation (7%), ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> including <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span> (5%), <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> (3%), <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span> (3%), <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> (3%), eyelash darkening (2%), <span class="product-label-link" type="condition" conceptid="4083923" conceptname="Growth of eyelashes">growth of eyelashes</span> (2%) and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span> (2%).</p>
<p>Nonocular adverse reactions reported at an incidence of 2% – 6% in these clinical studies in patients treated with tafluprost 0.0015% were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (6%), <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> (4%), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (3%) and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (2%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of tafluprost. Because postapproval adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span>: </span> <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>/<span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span></p>
<p>In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.1.1"></a><p></p>
<p class="First">Pregnancy Category C.</p>
<p>Teratogenic effects: In embryo-fetal development studies in rats and rabbits, tafluprost administered intravenously was teratogenic. Tafluprost caused increases in post-implantation losses in rats and rabbits and reductions in fetal body weights in rats. Tafluprost also increased the incidence of vertebral skeletal abnormalities in rats and the incidence of skull, brain and <span class="product-label-link" type="condition" conceptid="81670" conceptname="Congenital anomaly of spine">spine malformations</span> in rabbits. In rats, there were no adverse effects on embryo-fetal development at a dose of 3 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid that were 343 times the maximum clinical exposure based on C<span class="Sub">max</span>. In rabbits, effects were seen at a tafluprost dose of 0.03 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid during organogenesis that were approximately 5 times higher than the clinical exposure based on C<span class="Sub">max</span>. At the no-effect dose in rabbits (0.01 mcg/kg/day), maternal plasma levels of tafluprost acid were below the lower level of quantification (20 pg/mL).</p>
<p>In a pre- and postnatal development study in rats, increased mortality of newborns, decreased body weights and delayed pinna unfolding were observed in offsprings. The no observed adverse effect level was at a tafluprost intravenous dose of 0.3 mcg/kg/day which is greater than 3 times the maximum recommended clinical dose based on body surface area comparison.</p>
<p>There are no adequate and well-controlled studies in pregnant woman. Although animal reproduction studies are not always predictive of human response, ZIOPTAN should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.</p>
<p>Women of childbearing age/potential should have adequate contraceptive measures in place.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">A study in lactating rats demonstrated that radio-labeled tafluprost and/or its metabolites were excreted in milk. It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ZIOPTAN is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Use in pediatric patients is not recommended because of potential safety concerns related to increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> following long-term chronic use.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-7.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-8"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">Tafluprost is a fluorinated analog of prostaglandin F2α. The chemical name for tafluprost is 1-methylethyl (<span class="Italics">5Z</span>)-7-{(<span class="Italics">1R</span>, <span class="Italics">2R</span>, <span class="Italics">3R</span>, <span class="Italics">5S</span>)-2-[(<span class="Italics">1E</span>)-3,3-difluoro-4-phenoxy-1-butenyl}-3,5-dihydroxycyclopentyl]-5-heptenoate. The molecular formula of tafluprost is C<span class="Sub">25</span>H<span class="Sub">34</span>F<span class="Sub">2</span>O<span class="Sub">5</span> and its molecular weight is 452.53.</p>
<p>Its structural formula is:</p>
<div class="Figure"><img alt="image of tafluprost chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d51cbf25-003c-4ba7-86cf-921637ef37a0&amp;name=zioptan-01.jpg"></div>
<p>Tafluprost is a colorless to light yellow viscous liquid that is practically insoluble in water.</p>
<p>ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is supplied as a sterile solution of tafluprost with a pH range of 5.5 – 6.7 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">Osmolality</span> range of 260 – 300 mOsmol/kg.</p>
<p>ZIOPTAN contains Active: tafluprost 0.015 mg/mL; Inactives: glycerol, sodium dihydrogen phosphate dihydrate, disodium edetate, polysorbate 80, hydrochloric acid and/or sodium hydroxide (to adjust pH) and Water for Injection.</p>
<p>ZIOPTAN does not contain a preservative.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-9"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-9.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Tafluprost acid, a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-9.2"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>Following instillation, tafluprost is absorbed through the cornea and is hydrolyzed to the biologically active acid metabolite, tafluprost acid. Following instillation of one drop of the 0.0015% solution once daily into each eye of healthy volunteers, the plasma concentrations of tafluprost acid peaked at a median time of 10 minutes on both Days 1 and 8. The mean plasma C<span class="Sub">max</span> of tafluprost acid were 26 pg/mL and 27 pg/mL on Day 1, and Day 8, respectively. The mean plasma AUC estimates of tafluprost acid were 394 pg*min/mL and 432 pg*min/mL on Day 1 and 8, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.2"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span></p>
<p>Tafluprost, an ester prodrug, is hydrolyzed to its biologically active acid metabolite in the eye. The acid metabolite is further metabolized via fatty acid β-oxidation and phase II conjugation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.3"></a><p></p>
<p class="First"><span class="Bold">Elimination</span></p>
<p>Mean plasma tafluprost acid concentrations were below the limit of quantification of the bioanalytical assay (10 pg/mL) at 30 minutes following topical ocular administration of tafluprost 0.0015% ophthalmic solution.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-10"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-10.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Tafluprost was not carcinogenic when administered subcutaneously daily for 24 months at doses up to 30 mcg/kg/day in rats and for 18 months at doses up to 100 mcg/kg/day in mice (over 1600 and 1300 times, respectively, the maximum clinical exposure based on plasma AUC).</p>
<p>Tafluprost was not mutagenic or clastogenic in a battery of genetic toxicology studies, including an <span class="Italics">in vitro</span> microbial mutagenesis assay, an <span class="Italics">in vitro</span> chromosomal aberration assay in Chinese hamster lung cells, and an <span class="Italics">in vivo</span> mouse micronucleus assay in bone marrow.</p>
<p>In rats, no adverse effects on mating performance or fertility were observed with intravenous dosing of tafluprost at a dose of 100 mcg/kg/day (over 14000 times the maximum clinical exposure based on plasma C<span class="Sub">max</span> or over 3600 times based on plasma AUC).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-11"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<p class="First">In clinical studies up to 24 months in duration, patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> and baseline pressure of 23–26 mm Hg who were treated with ZIOPTAN dosed once daily in the evening demonstrated reductions in intraocular pressure at 3 and 6 months of 6–8 mmHg and 5–8 mmHg, respectively.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-12"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is supplied as a sterile solution in translucent low density polyethylene single-use containers packaged in foil pouches (10 single-use containers per pouch). Each single-use container has 0.3 mL solution corresponding to 0.0045 mg tafluprost.</p>
<p>NDC 0006-3931-30; Unit-of-Use Carton of 30.<br>NDC 0006-3931-54; Unit-of-Use Carton of 90.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span></p>
<p>Store refrigerated at 2–8°C (36–46°F). Store in the original pouch. After the pouch is opened, the single-use containers may be stored in the opened foil pouch for up to 28 days at room temperature: 20–25°C (68–77°F). Protect from moisture. Write down the date you open the foil pouch in the space provided on the pouch. Discard any unused containers 28 days after first opening the pouch.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-13"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling (<a href="#patinfo">Patient Information</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-13.1"></a><p></p>
<h2>17.1	Nightly Application</h2>
<p class="First">Advise patients to not exceed once daily dosing since more frequent administration may decrease the intraocular pressure lowering effect of ZIOPTAN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-13.2"></a><p></p>
<h2>17.2	Handling the Single-Use Container</h2>
<p class="First">Advise patients that ZIOPTAN is a sterile solution that does not contain a preservative. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-13.3"></a><p></p>
<h2>17.3	Potential for <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span></h2>
<p class="First">Advise patients about the potential for increased brown <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris, which may be permanent. Also inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of ZIOPTAN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-13.4"></a><p></p>
<h2>17.4	Potential for Eyelash Changes</h2>
<p class="First">Inform patients of the possibility of eyelash and vellus hair changes in the treated eye during treatment with ZIOPTAN. These changes may result in a disparity between eyes in length, thickness, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-13.5"></a><p></p>
<h2>17.5	When to Seek Physician Advice</h2>
<p class="First">Advise patients that if they develop a new ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and eyelid reactions, they should immediately seek their physician's advice concerning the continued use of ZIOPTAN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-13.6"></a><p></p>
<h2>17.6	Use with Other Ophthalmic Drugs</h2>
<p class="First">If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.7"></a><a name="section-13.7"></a><p></p>
<h2>17.7	Storage Information</h2>
<p class="First">Instruct patients on proper storage of cartons, unopened foil pouches, and opened foil pouches <span class="Italics">[see<a href="#S16"> How Supplied/Storage and Handling (16)</a>]</span>. Recommended storage for cartons and unopened foil pouches is to store refrigerated at 2–8°C (36–46°F). After the pouch is opened, the single-use containers may be stored in the opened foil pouch for up to 28 days at room temperature: 20–25°C (68–77°F). Protect from moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Manufactured by:<br>Laboratoire Unither<br>ZI de la Guerie<br>F-50211 COUTANCES Cedex<br>France</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 2012 Merck Sharp &amp; Dohme Corp., a subsidiary of<span class="Bold"> Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>USPI-PF-24521308R005</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="patinfo"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION<br>ZIOPTAN™ </span>(zye OP tan)<br>(tafluprost ophthalmic solution) 0.0015%</p>
<p>Read this Patient Information before you start using ZIOPTAN<span class="Bold">™</span> and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is ZIOPTAN?</span></p>
<p>ZIOPTAN is a prescription sterile eye drop solution. ZIOPTAN is used to lower the pressure in the eye (intraocular pressure) in people with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> when their eye pressure is too high. ZIOPTAN belongs to a group of medicines called prostaglandin analogs.</p>
<p>ZIOPTAN is not for use in children.</p>
<p><span class="Bold">What should I tell my doctor before using ZIOPTAN?</span></p>
<p><span class="Bold">Before you use ZIOPTAN, tell your doctor if you:</span></p>
<ul class="Disc">
<li>have or have had eye problems including any surgery on your eye or eyes</li>
<li>are using any other eye medicines</li>
<li>have any other medical problems</li>
<li>are pregnant or plan to become pregnant. It is not known if ZIOPTAN will harm your unborn baby. You should use an effective method of birth control while you use ZIOPTAN. If you become pregnant while using ZIOPTAN talk to your doctor right away.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if ZIOPTAN passes into your breast milk. Talk to your doctor about the best way to feed your baby if you use ZIOPTAN.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins, and herbal supplements.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take ZIOPTAN?</span></p>
<p>Read the Instructions for Use at the end of this Patient Information leaflet for additional instructions about the right way to use ZIOPTAN.</p>
<ul class="Disc">
<li>
<span class="Bold">Use 1 drop of ZIOPTAN in your eye (or eyes) each evening. </span>Talk to your doctor or pharmacist if you are not sure how to use ZIOPTAN.</li>
<li>Your ZIOPTAN may not work as well if you use it more than 1 time each evening.</li>
<li>If you use other medicines in your eye, wait at least 5 minutes between using ZIOPTAN and your other eye medicines.</li>
<li>Use your ZIOPTAN right away after opening. Each ZIOPTAN single-use container is sterile and is to be used 1 time then thrown away. Do not save any ZIOPTAN that may be left over after you use your medicine. Using ZIOPTAN that is not sterile may cause other eye problems.</li>
</ul>
<p><span class="Bold">What are the possible side effects of ZIOPTAN?</span></p>
<p><span class="Bold">ZIOPTAN may cause serious side effects including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">changes in the color of your eye (iris). </span>Your iris may become more brown in color while using ZIOPTAN. This color change may not go away when you stop using ZIOPTAN. If ZIOPTAN is used in 1 eye only, the color of that eye may always be a different color from the color of your other eye.</li>
<li>
<span class="Bold">darkening of the color of the skin around your eye (eyelid). </span>These skin changes usually go away when you stop using ZIOPTAN.</li>
<li>
<span class="Bold">increasing the length, thickness, color, or number of your eyelashes. </span>These eyelash changes usually go away when you stop using ZIOPTAN.</li>
<li>
<span class="Bold">hair growth on your eyelids. </span>This hair growth usually goes away when you stop using ZIOPTAN.</li>
</ul>
<p>The most common side effects of ZIOPTAN include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of your eye</li>
<li><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> formation</li>
<li><span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span></li>
<li><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></li>
</ul>
<p>Tell your doctor if you have any new eye problems while using ZIOPTAN including:</p>
<ul class="Disc">
<li>an eye injury</li>
<li>an <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infection</span></li>
<li>a sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span></li>
<li>eye surgery</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of and around your eye (<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>)</li>
<li>problems with your eyelids</li>
</ul>
<p>Additionally, the following side effects have been reported in general use:</p>
<ul class="Disc">
<li>worsening of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
</ul>
<p>Tell your doctor if you have any other side effects that bother you. </p>
<p>These are not all the possible side effects of ZIOPTAN. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store ZIOPTAN?</span></p>
<p><span class="Bold">Keep the foil pouches and ZIOPTAN single-use containers dry.</span></p>
<p><span class="Bold">Before opening the foil pouches:</span></p>
<ul class="Disc">
<li>Store the unopened foil pouches in a refrigerator between 36°F to 46°F (2°C to 8°C).</li>
<li>Do not open the pouch containing ZIOPTAN until you are ready to use the eye drops.</li>
</ul>
<p><span class="Bold">After opening the foil pouch:</span></p>
<ul class="Disc">
<li>Store the opened foil pouch at room temperature, between 68°F to 77°F (20°C to 25°C), for up to 28 days.</li>
<li>Throw away all unused ZIOPTAN single-use containers in the opened foil pouch after 28 days.</li>
<li>Keep the ZIOPTAN single-use containers in their original foil pouch.</li>
<li>After opening the foil pouch, refrigeration is not required.</li>
</ul>
<p><span class="Bold">Keep ZIOPTAN and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of ZIOPTAN.</span></p>
<p>Do not use ZIOPTAN for a condition for which it was not prescribed. Do not give ZIOPTAN to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about ZIOPTAN. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ZIOPTAN that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in ZIOPTAN?</span></p>
<p><span class="Bold">Active ingredients: </span>tafluprost</p>
<p><span class="Bold">Inactive ingredients: </span>glycerol, sodium dihydrogen phosphate dihydrate, disodium edetate, and polysorbate 80, hydrochloric acid and/or sodium hydroxide, and water</p>
<p><span class="Bold">Instructions for Use</span></p>
<p>Read these Instructions for Use before using your ZIOPTAN and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">Important:</span></p>
<ul class="Disc">
<li><span class="Bold">ZIOPTAN is for the eye only. Do not swallow ZIOPTAN.</span></li>
<li>ZIOPTAN single-use containers are packaged in a foil pouch.</li>
<li>
<span class="Bold">Do not </span>use the ZIOPTAN single-use containers if the foil pouch is opened. </li>
<li>Write down the date you open the foil pouch in the space provided on the pouch.</li>
</ul>
<p><span class="Bold">Every time you use ZIOPTAN:</span></p>
<table width="85%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="50">
<col align="center" valign="middle" width="35%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="Bold">Step 1.</span></td>
<td class="Rrule" align="left">Wash your hands.</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Step 2.</span></td>
<td class="Rrule" align="left">Take the strip of single-use containers from the foil pouch.</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Step 3.</span></td>
<td class="Rrule" align="left">Pull off one single-use container from the strip.</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Step 4.</span></td>
<td class="Rrule" align="left">Put the remaining strip of single-use containers back in the foil pouch and fold the edge to close the pouch.</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2"> </td>
<td class="Botrule Rrule" align="center" rowspan="2">
<a name="figA"></a><img alt="image of Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d51cbf25-003c-4ba7-86cf-921637ef37a0&amp;name=zioptan-02.jpg"><br><span class="Bold">Figure A</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Step 5.</span></td>
<td class="Rrule" align="left">Hold the single-use container upright. Make sure that your ZIOPTAN medicine is in the bottom part of the single-use container.<br><span class="Bold">See<a href="#figA"> Figure A</a>.</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" colspan="2"> </td>
<td class="Botrule Rrule" align="center" rowspan="2">
<a name="figB"></a><img alt="image of Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d51cbf25-003c-4ba7-86cf-921637ef37a0&amp;name=zioptan-03.jpg"><br><span class="Bold">Figure B</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Step 6.</span></td>
<td class="Rrule" align="left">Open the single-use container by twisting off the tab.<br><span class="Bold">See<a href="#figB"> Figure B</a>.</span>
</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Step 7.</span></td>
<td class="Rrule" align="left">Tilt your head backwards. If you are unable to tilt your head, lie down.</td>
<td class="Botrule Rrule" align="center" rowspan="2">
<a name="figC"></a><img alt="image of Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d51cbf25-003c-4ba7-86cf-921637ef37a0&amp;name=zioptan-04.jpg"><br><span class="Bold">Figure C</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold"><br>Step 8.</span></td>
<td class="Botrule Rrule" align="left">
<br>Place the tip of the single-use container close to your eye. Be careful not to touch your eye with the tip of the single-use container.<br><span class="Bold">See<a href="#figC"> Figure C</a>.</span>
</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Step 9.</span></td>
<td class="Rrule" align="left">Pull your lower eyelid downwards and look up.</td>
<td class="Botrule Rrule" align="center" rowspan="2">
<a name="figD"></a><img alt="image of Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d51cbf25-003c-4ba7-86cf-921637ef37a0&amp;name=zioptan-05.jpg"><br><span class="Bold">Figure D</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="Bold"><br>Step 10.</span></td>
<td class="Rrule" align="left">
<br>Gently squeeze the container and let 1 drop of ZIOPTAN <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> into the space between your lower eyelid and your eye. If a drop misses your eye, try again.<br><span class="Bold">See<a href="#figD"> Figure D</a>.</span>
</td>
</tr>
</tbody>
</table>
<ul class="Disc">
<li>If your doctor has told you to use ZIOPTAN drops in both eyes, repeat Steps 7 to 10 for your other eye.</li>
<li>There is enough ZIOPTAN in one single-use container for both of your eyes.</li>
<li><span class="Bold">Throw away the opened single-use container with any remaining ZIOPTAN right away.</span></li>
</ul>
<p><span class="Bold">This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC., </span>Whitehouse Station, NJ 08889, USA</p>
<p>Manufactured by:<br>Laboratoire Unither<br>ZI de la Guerie<br>F-50211 COUTANCES Cedex<br>France</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 2012 Merck Sharp &amp; Dohme Corp., a subsidiary of<span class="Bold"> Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>Revised: 08/2013</p>
<p>USPPI-PF-24521308R005</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 30 Ampule Carton</span></p>
<p>NDC 0006-3931-30</p>
<p><span class="Bold">ZIOPTAN<span class="Sup">™</span><br>(tafluprost ophthalmic<br>solution)</span><br>0.0015%</p>
<p><span class="Bold">For Topical Application in the Eye</span><br><span class="Bold">REFRIGERATE (2-8°C or 36-46°F)</span></p>
<p><span class="Bold">Single-Use Containers</span><br><span class="Bold">Preservative-Free, Sterile</span></p>
<p><span class="Bold">Contains:</span><br><span class="Bold">Active: </span>tafluprost 0.0015%<br>(4.5 mcg per single-use container)<br><span class="Bold">Inactive ingredients: </span>glycerol, sodium dihydrogen<br>phosphate dihydrate, disodium edetate, polysorbate 80,<br>Water for Injection. Hydrochloric acid and/or<br>sodium hydroxide are added to adjust pH.</p>
<p><span class="Bold">Rx only<br>30 Single-Use Containers:</span><br>3 pouches × 10 single-use containers<br>(0.3 mL each)</p>
<p>6010903</p>
<div class="Figure"><img alt="Principal Display Panel - 30 Ampule Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d51cbf25-003c-4ba7-86cf-921637ef37a0&amp;name=zioptan-06.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZIOPTAN 		
					</strong><br><span class="contentTableReg">tafluprost solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0006-3931</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TAFLUPROST</strong> (TAFLUPROST) </td>
<td class="formItem">TAFLUPROST</td>
<td class="formItem">0.0045 mg  in 0.3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0006-3931-30</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0006-3931-10</td>
<td class="formItem">10  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.3 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0006-3931-54</td>
<td class="formItem">9  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0006-3931-10</td>
<td class="formItem">10  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">0.3 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0006-3931-36</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">0.3 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202514</td>
<td class="formItem">02/10/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merck Sharp &amp; Dohme Corp.
							(001317601)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Laboratoire Unither</td>
<td class="formItem"></td>
<td class="formItem">574139809</td>
<td class="formItem">MANUFACTURE(0006-3931), PACK(0006-3931)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Asahi Glass Company, Limited</td>
<td class="formItem"></td>
<td class="formItem">695073924</td>
<td class="formItem">API MANUFACTURE(0006-3931)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>feaedfa1-7511-48a2-a33c-4200c90b57cd</div>
<div>Set id: d51cbf25-003c-4ba7-86cf-921637ef37a0</div>
<div>Version: 7</div>
<div>Effective Time: 20130802</div>
</div>
</div> <div class="DistributorName">Merck Sharp &amp; Dohme Corp.</div></p>
</body></html>
